Stimulator of Interferon Genes (STING)

Overview

STING1 (Stimulator of interferon Genes 1), encoded by the gene TMEM173 (also catalogued as Wikidata Q18055374), is a transmembrane adaptor protein that serves as a central hub in the innate immune sensing pathway. Located on the endoplasmic reticulum membrane, STING1 functions downstream of cyclic GMP-AMP synthase (cGAS), which detects cytosolic double-stranded DNA from damaged, infected, or malignant cells. Upon activation by cyclic dinucleotides (CDNs) — including the second messenger cGAMP produced by cGAS — STING1 undergoes conformational changes that recruit and activate TBK1 and IRF3, ultimately driving transcription of type I interferons and other pro-inflammatory cytokines. This signaling cascade, collectively known as the cGAS–STING pathway, bridges the detection of nucleic acid danger signals to a robust adaptive immune response, making the p53/cGAS/STING axis a critical checkpoint in tumor surveillance and antiviral defense.

Because STING1 occupies a nodal position in innate immunity, it has attracted intense interest as a therapeutic target in oncology and inflammatory disease. Pharmacological agonists of STING1 can reprogram the immunosuppressive tumor microenvironment by recruiting and activating dendritic cells and other immune effectors, thereby potentiating cancer immunotherapy. Conversely, in conditions of chronic sterile inflammation — such as pulmonary fibrosis — pathological STING1 activity in macrophages drives tissue damage, making its targeted silencing equally therapeutically relevant.

Recent Publications Summary

Recent studies have continued to position Stimulator of interferon Genes (STING) as a central node in innate immune signaling, with both agonist- and inhibitor-based strategies being explored across inflammatory disease, cancer, and fibrosis. A molecular-glue approach reported that benzofuran derivatives can potently inhibit STING by inducing aberrant oligomerization, including an unconventional “head-to-head” dimerization configuration rather than canonical linear polymers, and that this activity extended across multiple STING contexts, including 2’,3’-cGAMP-, dsDNA-, gain-of-function SAVI-associated mutants, and HSV-1–activated STING; the lead compound also reduced type I interferons, interferon-stimulated genes, and pro-inflammatory cytokines in patient-derived samples 42547770Aug. In a separate translational review, TMEM173 (STING) was highlighted as an immune-activating member of the TMEM family with relevance to the tumor immune microenvironment, while another review summarized the growing interest in benzimidazole-based non-CDN STING agonists as more stable and potentially orally usable alternatives to cyclic dinucleotides for cancer immunotherapy 41864016Mar41785706Mar.

Several publications focused on leveraging STING activation to enhance antitumor immunity, often in combination with other therapies or delivery platforms. An X-ray-responsive nanoplatform was designed to release Mn2+ in tumors, sensitizing cGAS to cytosolic DNA and amplifying STING signaling, which increased interferon-β secretion and dendritic cell maturation and improved radio-immunotherapy when combined with radiation therapy 42023514Apr. A “self” signal-suppressed metal-organic framework nanodrug coupled CD47 blockade with the STING agonist diABZI, aiming to enhance chemodynamic therapy and immunotherapy; in mouse melanoma models, the formulation showed tumor-targeting activity and suppressed tumor growth with prolonged survival 41723989Feb. Another study found that co-delivery of a STING agonist with Indoleamine 2,3-dioxygenase 1 (IDO1) blockade produced synergistic antitumor effects by targeting myeloid cells, especially dendritic cells, and promoting antigen cross-presentation, dendritic cell maturation, cytokine secretion, cytotoxic T-cell priming, tumor suppression, and survival benefit; the antitumor effect depended on host STING 41702511Feb. In oral cancer, a peptide hydrogel-liposome composite was developed to prolong local cyclic dinucleotide release, addressing the need for frequent intratumoral administration of STING agonists 41702512Feb. A review also discussed STING agonist development as a broader strategy in cancer immunotherapy 41785706Mar.

Other studies examined STING in nonmalignant disease, especially fibrotic lung pathology, where STING signaling was described as a driver of disease in alveolar macrophages. One inhalable lipid nanoparticle system delivered CRISPR-Cas9 mRNA for macrophage-specific Sting1 gene editing, achieving selective pulmonary macrophage uptake, suppression of downstream STING signaling, reduced pro-fibrotic cytokine secretion, and amelioration of pulmonary fibrosis in a murine model 41795185Mar. A related inhalable polymeric PROTAC nanococktail was designed to degrade STING in senescence-associated epithelial compartments while also targeting another profibrotic regulator, with the STING-degrading component intended to suppress senescence-associated inflammatory signaling linked to impaired alveolar repair 42341263Jun. Together, these studies emphasize the therapeutic versatility of STING modulation, ranging from inhibition in autoinflammatory and fibrotic settings to activation in cancer and radio-immunotherapy, and suggest that delivery technologies and pathway-combination strategies are key to its clinical translation 42547770Aug42023514Apr41795185Mar42341263Jun.

What Changes, What Holds

1. STING can now be inhibited through induced abnormal oligomerization, broadening its druggability beyond agonism
NEW DIRECTION Benzofuran “molecular-glue” inhibitors extend the STING story beyond the Overview’s emphasis on activation for cancer and suppression in fibrosis: they argue that STING can be pharmacologically shut down by enforcing an atypical assembly state, including activity against gain-of-function and virus-activated contexts 42547770Aug. That widens the therapeutic map to direct pathway blockade across interferon-driven disease states, while leaving the core cGAS–STING signaling framework intact.

2. STING agonism remains a valid antitumor strategy, but delivery and combination design appear to be the real constraint
REINFORCES The new work does not alter the Overview’s central view that STING activation can reprogram the tumor microenvironment and support cancer immunotherapy; it sharpens that idea by showing how efficacy may depend on improving local exposure, coupling to radiation or checkpoint-style interventions, and overcoming the practical limits of cyclic dinucleotide use 42023514Apr41723989Feb. The main update is translational, not conceptual: STING still points in the same direction, but the path to benefit looks formulation-dependent.

3. Local STING modulation is emerging as a disease-specific therapy for fibrosis without changing the core lung-injury model
NEW DIRECTION macrophage-directed Sting1 editing and degraders extend the Overview’s note that pathological STING drives pulmonary fibrosis by moving from general therapeutic interest to highly targeted, inhaled interventions that aim to suppress the pathway in precise compartments 41795185Mar42341263Jun. That adds a new practical dimension: STING can be edited or degraded in situ, not just inhibited systemically. The underlying fibrotic role is confirmed, but the delivery logic and cell specificity are new.

Overview update candidates: targeted inhibition/editing of STING in fibrotic lung disease; STING inhibition by induced abnormal oligomerization; delivery-dependent combination strategies for STING agonism in cancer.